March 10, 2017

Taking Insulin e-Therapy to Heart

Cardiovascular (CVD) patients receiving personalized insulin therapy using a software-based hyperglycemia management program had dramatically fewer hospital readmissions than those given standard care, according to two studies from Mountain States Health Alliance health care system.

The retrospective studies focused on readmission rates for three patient populations admitted for CVD indications between January and December 2015. The results showed that compared with patients treated with standard care, coronary artery bypass graft patients were readmitted 68% less often with the software program; congestive heart failure patients were readmitted 65% less often; and acute myocardial infarction patients were readmitted 36% less often, the investigators reported at the 2016 Annual Diabetes Technology Meeting.

February 16, 2017

New Research Further Validates Benefits of Personalized Diabetes Therapy Management Across the Continuum of Care

Two studies presented at the International Conference on Advanced Technologies & Treatments for Diabetes offer additional evidence of how Glytec’s disruptive technologies achieve dramatic and sustained impact on glucose control.

The 10th Annual International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2017) showcases additional evidence that use of Glytec’s patented eGlycemic Management System®, or eGMS®, leads to dramatic improvements in diabetes control and patient outcomes in both acute and outpatient settings. Two studies presented by diabetologist and researcher, Dr. Bruce Bode, find that personalized therapy management facilitated through Glytec’s eGMS® effectively reduces hemoglobin A1C, incidence of hypoglycemia and time to prescribed glucose target, all primary measures of diabetes control and patient outcomes.

February 7, 2017

Novant Health Partners with Glytec to Advance Leadership Position in Patient-Centered Diabetes Care

Glytec’s solution will enable the 14-hospital health system to achieve best practice, reduce variability and standardize care for patients with diabetes.

Becoming a national leader in diabetes care is a commitment Novant Health, headquartered in Winston-Salem, North Carolina, will advance through a new partnership with Glytec. The company’s patented eGlycemic Management System® (eGMS®) will be a focal point of the health system’s diabetes service line, offering clinicians a comprehensive set of tools, technologies and processes proven to achieve full adoption of basal-bolus insulin therapy, the standard of care and best practice endorsed by the American Diabetes Association (ADA) and American Association of Clinical Endocrinologists (AACE).

January 25, 2017

Grady Health System Improves Diabetes Care With Glytec’s eGlycemic Management System

Glytec’s system for personalized diabetes therapy management translates to better quality of care at Atlanta’s Grady Health System.

In its quest to ensure high quality care for critically ill patients, Atlanta’s Grady Health System has implemented the evidence-based Glytec eGlycemic Management System® (eGMS®), a personalized diabetes therapy management solution.

December 20, 2016

Digital Insulin Management Cuts Hospital Readmissions for CV Patients

The findings come as CMS targets cardiac procedures in both its hospital readmission reduction program and in a bundled payment model set to take effect July 1, 2017.

Glytec, which has FDA clearance for a cloud-based system to manage insulin dosing, selected MSHA as a research site for its electronic glucose management system, or eGMS. According to the studies Parsons and Mumpower presented in November at the Diabetes Technology Meeting showcase, eGMS produced sharp drops in readmission rates in 3 areas of cardiac care.

November 14, 2016

Dramatic Readmission Reductions for CABG, CHF and AMI Attributed to Glytec’s eGlycemic Management System

Two studies presented at the 16th Annual Diabetes Technology Meeting showcase readmission reductions as high as 68% with Glytec’s solution.

Two new studies presented at last week’s Diabetes Technology Meeting further validate the ability of Glytec’s eGlycemic Management System® (eGMS®) to achieve dramatic readmission reductions for patient populations at the center of new at-risk and value-based reimbursement models, including the CMS Hospital Readmission Reduction Program (HRRP) and impending bundled payment for coronary artery bypass graft surgery (CABG).

October 11, 2016

Study Conducted at Fred Hutch Shows Transplant Patients Benefit from Glytec’s System for Computer-Guided Glucose Management

Study shows hospitalized transplant patients achieve and sustain improved glucose levels when managed on Glucommander from Glytec.

As a pioneer in technology for glycemic management, Glytec is pleased to share the results of a recent study conducted at the Fred Hutchinson Cancer Research Center in Seattle, Washington. The prospective study, led by Cora Espina Erickson, ARNP, CWCN and published by Bone Marrow Transplantation,1 demonstrates that stringent glucose control among allogeneic hematopoietic cell transplantation (HCT) patients is feasible using Glucommander(TM), the computer-guided glucose management system from Glytec.

October 5, 2016

CHI Franciscan Updating Glucose Management Tools, Seeking Robust EHR Integration

CHI Franciscan Health is preparing to implement a new SaaS-based glucose management system that offers proprietary insulin dosing algorithms, analytics and reporting, automated surveillance and alerting, but the real selling point was more seamless EHR integration.

The perceived value of medical devices and ancillary software systems is increasingly tied to how seamlessly they integrate with EHR platforms from Epic or Cerner. That was the case when CHI Franciscan Health in Tacoma, Wash., recently evaluated glucose management systems. One key reason the eight-hospital system chose to implement Glytec’s eGlycemic Management System (eGMS) was its robust integration with Epic.

October 4, 2016

Study Published by Journal of Diabetes Science and Technology Demonstrates Glytec’s Superiority in Meeting ADA Guidelines

Better patient outcomes point to use of a fully automated insulin dosing decision support system as the new standard of care for basal-bolus therapy.

A study published in the Journal of Diabetes Science and Technology (JDST) provides further evidence that Glytec’s patented eGlycemic Management System® (eGMS®) is safer and more effective than traditional approaches to managing basal-bolus therapy. With some 40% of hospitalized patients receiving insulin therapy during their stay, the consequences of inadequate and imprecise dosing — including increased risk of complications and mortality, longer lengths of stay, and higher readmission rates — pose significant cost and quality improvement opportunities for hospitals.

September 30, 2016

Hawaii Pacific Health Receives 2016 HIMSS Enterprise Davies Award Based in Part on Success With Glytec’s eGMS®

Our client, Hawaii Pacific Health, was named a HIMSS Enterprise Davies Award recipient based in part on its success implementing Glytec’s eGlycemic Management System® to support computer-based insulin dosing and a new hypoglycemia protocol.

The results were better glucose control with computer-directed insulin dosing system versus usual care. 39.8% of all glucose values in the ICU setting were above the recommended limit (glucose 180 mg/dl) with usual care. With computer-directed insulin dosing system for intravenous insulin, the hyperglycemia rate was much lower representing just 16.6% of all glucose values.

September 22, 2016

CHI Franciscan Health Selects Glytec’s eGMS® for Precision Diabetes Management

The eGMS® solution suite includes real-time insulin dosing, robust analytics and reporting, automated surveillance and alerting, clinical transformation services, and more.

CHI Franciscan Health of Tacoma, Washington has recently turned to Glytec for its comprehensive eGlycemic Management System®, or eGMS®, which includes FDA-cleared technology for both intravenous and subcutaneous real-time insulin dosing.

September 13, 2016

Palmetto Health to Use Glytec’s eGlycemic Management System® for Diabetes Care

The FDA-cleared technology solution will help facilitate best practices for glycemic management across the integrated health care system.

Palmetto Health, the largest integrated health care system in the South Carolina Midlands region, has selected Glytec’s eGlycemic Management System®, or eGMS®, to support quality of care for patients with diabetes. The cloud-hosted eGMS® software-as-a-service (SaaS) solution will be used enterprise-wide, across all of Palmetto Health’s clinical disciplines.

July 8, 2016

Reduced Inpatient Hypoglycemia With Electronic Glycemic Management System

An electronic glycemic management system (eGMS) may help lower rates of hypoglycemia and lower average blood glucose levels in hospitalized patients compared with usual care, according to a new study.

The aim of this study was to compare hypoglycemia rates in patients managed with an eGMS compared with patients managed by usual care. In this current study, there were 45,335 patients treated with usual care and 13,351 patients treated with eGMS. The target blood glucose was pegged at 100 mg/dL to 180 mg/dL. The researchers evaluated how many patients experiencing mild to moderate hypoglycemia (<70 mg/dL, <60 mg/dL, and <50 mg/dL) and severe hypoglycemia (<40 mg/dL) in the eGMS group compared with the usual care group.

July 2, 2016

Electronics Said to Reduce Hypoglycemic Events

New data presented at AACE shows hypoglycemic events are less likely in patients with diabetes treated with an electronic glycemic management system.

In an interview, Joseph Aloi, MD, section chief of endocrinology and metabolism at Wake Forest Baptist Medical Center in Winston-Salem, North Carolina, told Diabetes in Control that, “Patients who were treated with the [electronic glycemic management system] had a statistically lower incidence of hypoglycemic events and lower average blood glucose compared with [usual care], suggesting it may be easier to achieve glycemic targets safely for patients in the hospital setting.

June 20, 2016

Glytec Presents Evidence on How Using Data to Deliver Insulin Improves Outcomes

Using an algorithm to recommend insulin dosing, both in and out of the hospital, was shown to improve glycemic control and aid population health management.

The march toward value-based care is occurring on many fronts, with diabetes quality metrics front and center. Providers from giant hospital systems to primary care practices are looking for ways to find savings—and make patients healthier. In this mix is Glytec, a 10-year-old company founded on the idea that taking guesswork and time out of insulin dosing, first in hospital settings and then outside them, could dramatically reduce episodes of hypo- and hyperglycemia. This would provide savings and lead to better glycated hemoglobin (A1C) levels for patients with previously uncontrolled diabetes.

June 16, 2016

Glytec’s Glucommander and eGlycemic Management System Featured in Five Studies Presented at The American Diabetes Association’s 76th Scientific Sessions

Wide range of studies further demonstrates significant impact in the emergency department, hospital and outpatient settings.

Glytec, the pioneer and leader in providing innovative, FDA-cleared glucose management software solutions, today announced that the company has presented five abstracts addressing a range of issues related to diabetes care at the American Diabetes Association’s 76th Scientific Sessions in New Orleans, Louisiana, June 10-14, 2016. The American Diabetes Association (ADA) brings together global leaders to discuss advancements in diabetes research and care.

June 5, 2016

Glucommander Linked to Improved Blood Glucose Levels

The inclusion of a computer-guided program (Glucommander) as a component of diabetic ketoacidosis management was associated with significantly less hypoglycemia and faster time to normalization of blood glucose and bicarbonate than standard treatment of diabetic ketoacidosis, according to a new retrospective multicenter study.

The data were presented at the American Association of Clinical Endocrinologists (AACE) 25th Annual Scientific & Clinical Congress. The study also demonstrated a significant difference in length of hospital stay for patients treated with Glucommander compared with standard protocol (3.2 vs 4.5 days).

June 1, 2016

Glytec Presents Key Studies at the AACE 25th Annual Scientific and Clinical Congress

Experts demonstrate the ability of automated glucose management to significantly reduce rates of hypoglycemia and DKA.

Glytec, the pioneer and leader in providing innovative, FDA cleared glucose management software solutions, today announced that two abstracts addressing the approach to care for patients suffering from hypoglycemia and diabetic ketoacidosis (DKA) were presented at the American Association of Clinical Endocrinologists (AACE) 25th Annual Scientific and Clinical Congress, held from May 25-29th in Orlando, Florida.

May 31, 2016

Computer Algorithms Managing Insulin Dosages Result in Better Glycemic Control

When insulin dosages are calculated using computer algorithms to reach target blood glucose levels, hospitalized patients are less likely to have episodes of low blood sugar and recover sooner from diabetic ketoacidosis than when insulin dosages are calculated without an algorithm.

Those were key findings from two multisite studies presented at the American Association of Clinical Endocrinologists meeting, held May 25-29 in Orlando, Florida. “Computer algorithms facilitate doing the right thing,” said Dr. Joseph A. Aloi, professor of endocrinology and metabolism at Wake Forest Baptist Medical Center in Winston-Salem, North Carolina, and the studies’ principal investigator.

May 16, 2016

Orange Regional Medical Center Receives HIMSS Stage 7 Award Based Largely on Glytec’s Insulin Decision Support Solution

Our client, Orange Regional Medical Center, received a HIMSS Analytics Stage 7 Award based largely on its success implementing Glytec’s eGlycemic Management System® to support computer-based precision insulin dosing.

HIMSS Analytics® awarded Orange Regional Medical Center (ORMC), in Middletown, N.Y., with a Stage 7 Award. The award represents ORMC’s attainment of the highest level on the Electronic Medical Record Adoption Model (EMRAM)℠.